Metal-Based Complexes in Cancer Treatment
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 46608
Special Issue Editors
Interests: gold-based anticancer drugs; auranofin; thioredoxin reductase; ovarian cancer; cancer cell metabolism; proteomics; redox proteomics
Interests: anticancer agents; metals in medicine; Medicinal bioinorganic chemistry; drug delivery; antibacterial agents; metal complexes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metal-based complexes contribute a vital part in the available arsenal of cytotoxic agents today. Platinum(II) complexes, specifically targeting genomic DNA (e.g., cisplatin and carboplatin), are widely used in the clinic for the treatment of various cancers. Nearly 50% of cancer patients, who undergo chemotherapy, receive a platinum drug either alone or in combination therapy. Despite their central role in cancer chemotherapy, platinum drugs suffer serious drawbacks such as the limited spectrum of antitumor activities, systemic dose-related toxicity, and the frequent induction of drug resistance, often leading to treatment failure. These observations have prompted a strong interest in the investigation of nonplatinum metal-based drugs as an effective alternative. Several other platinum and nonplatinum metal complexes (e.g., Ti, Pd, Ru, Au) have shown potent cytotoxic and antitumor effects. Unlike to platinum drugs, these are often relying on DNA-independent biochemical mechanisms such as targeting tumor-associated proteins and induction of immunogenic antitumor properties for their therapeutic effects. Notably, a few of these drugs are already in clinical trials, and several are awaiting ethical approval to enter the trial phase. This Special Issue will include original research and review articles on the use of platinum and nonplatinum metal complexes in cancer therapy. In particular, papers focusing on the design and developing targeted metal-based anticancer agents, understanding their mechanisms of action, and innovative drug delivery approaches will be considered. Topics of interest for this Special Issue include but are not limited to the following:
- medicinal chemistry of metal-based anticancer drugs;
- synthesis/improvement of platinum and nonplatinum metal complexes;
- mechanisms of action/biological targets of metal-based drugs;
- clinical applications of metal-based anticancer agents;
- uptake, toxicity, and resistance of metal-based anticancer agents;
- metal-based complexes in targeted drug delivery;
- metal-based drugs in cancer combinatorial therapy
Dr. Tania Gamberi
Dr. Muhammad Hanif
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metal-based anticancer drugs
- platinum and nonplatinum metal complexes
- mechanisms of action/biological targets of metal-based drugs
- clinical applications of metal-based anticancer agents
- cellular uptake, toxicity, and resistance of metal-based anticancer agents
- targeted drug delivery of metal-based compounds
- metal-based drugs in cancer combinatorial therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.